Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis-Reference-Cited by-同舟云学术

Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis

Published:2022-04 Issue:4 Volume:28 Page:211.e1-211.e9
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Gabanti Elisa,Borsani Oscar,Colombo Anna Amelia,Zavaglio Federica^ORCID,Binaschi Luana,Caldera Daniela,Sciarra Roberta,Cassinelli Gabriela,Alessandrino Emilio Paolo,Bernasconi Paolo,Ferretti Virginia Valeria,Lilleri Daniele^ORCID,Baldanti Fausto

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference29 articles.

1. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation;Ljungman;Haematologica,2006

2. Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection;Gabanti;Biol Blood Marrow Transplant,2015

3. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant;Goodrich;Ann Intern Med,1993

4. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial;Winston;Ann Intern Med,1993

5. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation;Winston;Clin Infect Dis,2003

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis;Bone Marrow Transplantation;2024-07-20

2. Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience;European Journal of Haematology;2024-06-21

3. Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study;Transplant Infectious Disease;2024-05-06

4. Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation;British Journal of Haematology;2024-04-06

5. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis;Turkish Journal of Hematology;2024-03-04